Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technol… Read more
Kuros Biosciences AG (CSBTF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.035x
Based on the latest financial reports, Kuros Biosciences AG (CSBTF) has a cash flow conversion efficiency ratio of -0.035x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.68 Million) by net assets ($76.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kuros Biosciences AG - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Kuros Biosciences AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kuros Biosciences AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kuros Biosciences AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Solid Power Inc
NASDAQ:SLDP
|
-0.044x |
|
Hainan Expressway Co Ltd
SHE:000886
|
-0.028x |
|
Zhongtong Bus Holding Co Ltd
SHE:000957
|
0.118x |
|
SandRidge Energy Inc
NYSE:SD
|
0.062x |
|
Orrstown Financial Services Inc
NASDAQ:ORRF
|
0.039x |
|
PT Vale Indonesia Tbk
F:XT3B
|
0.044x |
|
L.D.C. S.A.
F:LC4
|
N/A |
|
Wetown Electric Group Co Ltd
SHG:688226
|
0.010x |
Annual Cash Flow Conversion Efficiency for Kuros Biosciences AG (2004–2024)
The table below shows the annual cash flow conversion efficiency of Kuros Biosciences AG from 2004 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $58.75 Million | $3.14 Million | 0.053x | +134.27% |
| 2023-12-31 | $56.71 Million | $-8.84 Million | -0.156x | -46.14% |
| 2022-12-31 | $68.86 Million | $-7.35 Million | -0.107x | -50.63% |
| 2021-12-31 | $76.98 Million | $-5.45 Million | -0.071x | +35.13% |
| 2020-12-31 | $84.60 Million | $-9.24 Million | -0.109x | +21.63% |
| 2019-12-31 | $77.86 Million | $-10.85 Million | -0.139x | +16.98% |
| 2018-12-31 | $76.48 Million | $-12.84 Million | -0.168x | -14.97% |
| 2017-12-31 | $73.14 Million | $-10.68 Million | -0.146x | +37.09% |
| 2016-12-31 | $38.32 Million | $-8.89 Million | -0.232x | +93.82% |
| 2015-12-31 | $669.00K | $-2.51 Million | -3.758x | -514.73% |
| 2014-12-31 | $-26.22 Million | $-23.76 Million | 0.906x | +119.99% |
| 2013-12-31 | $4.23 Million | $-19.17 Million | -4.532x | -293.95% |
| 2012-12-31 | $10.03 Million | $-11.54 Million | -1.150x | -252.56% |
| 2011-12-31 | $-11.68 Million | $-8.81 Million | 0.754x | +206.14% |
| 2010-12-31 | $6.59 Million | $-4.68 Million | -0.710x | +61.61% |
| 2009-12-31 | $8.24 Million | $-15.25 Million | -1.850x | -111.33% |
| 2008-12-31 | $31.86 Million | $-27.89 Million | -0.876x | -983.67% |
| 2007-12-31 | $54.43 Million | $-4.40 Million | -0.081x | +87.07% |
| 2006-12-31 | $45.90 Million | $-28.67 Million | -0.625x | -70.75% |
| 2005-12-31 | $74.01 Million | $-27.08 Million | -0.366x | -29.32% |
| 2004-12-31 | $80.17 Million | $-22.68 Million | -0.283x | -- |